首页> 外文期刊>JAMA: the Journal of the American Medical Association >Antiviral Therapy and Hepatitis B Virys-Related Hepatocellular Carcinoma Recurrence
【24h】

Antiviral Therapy and Hepatitis B Virys-Related Hepatocellular Carcinoma Recurrence

机译:抗病毒治疗和乙型肝炎病毒相关的肝细胞癌复发

获取原文
获取原文并翻译 | 示例
           

摘要

To the Editor: Although using antiviral therapy to suppress hepatitis B virus (HBV) replication after curative resection of hepatocellular carcinoma (HCC) is thought to potentially reduce the rate of HCC recurrence, studies regarding the efficacy of nucleoside analogues in this clinical setting are limited and thus controversial.1 in the study by Dr Wu and colleagues,2 the authors used the Taiwan National Health Insurance Research Database for analysis and reported that the use of a nucleoside analogue was associated with a lower risk of HCC recurrence among patients with HBV-related HCC after liver resection.
机译:致编辑:尽管据认为治愈性切除肝细胞癌(HCC)后使用抗病毒治疗抑制乙型肝炎病毒(HBV)复制可能会降低HCC复发率,但有关这种临床环境中核苷类似物功效的研究仍然有限1在Wu博士及其同事的研究中2,作者使用了台湾国家健康保险研究数据库进行分析,并报告说,使用核苷类似物可以降低HBV-HCC患者HCC复发的风险。肝切除后相关的HCC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号